氨溴索应用于慢性阻塞性肺疾病并肺结核患者中的疗效研究

Research on Curative Effect of Ambroxol in Patients with Chronic Obstructive Pulmonary Diseases Combined with Pulmonary Tuberculosis

目的探讨氨溴索应用于慢性阻塞性肺疾病(COPD)并肺结核患者中的疗效。方法方便选择2016年5月—2017年5月该院收治的COPD并肺结核患者88例,以随机数字表将其分为对照组(采取常规对症治疗与抗结核治疗)与研究组(在对照组的基础上应用氨溴索治疗),每组44例。评价两组临床疗效与不良反应。结果两组患者治疗效果对比中,研究组总有效率93.18%高于对照组75.00%(χ2=5.436,P=0.012)。研究组治疗不良反应11.36%与对照组15.91%对比差异无统计学意义(χ2=0.386,P=0.072)。治疗后研究组PEF、FVC与FEV1/FVC指标均高于对照组(t=3.585、3.859、5.856,P=0.023,0.021,0.009)。结论氨溴索应用于COPD并肺结核患者中疗效确切,且不会增加药物不良反应,适于临床推广。

Objective To study the curative effect of ambroxol in patients with chronic obstructive pulmonary diseases combined with pulmonary tuberculosis. Methods 88 cases of patients with COPD combined with pulmonary tuberculosis admitted and treated in our hospital from May 2016 to May 2017 were convenient selected and randomly divided into two groups,the control group used the routine systematic therapy and anti tuberculosis treatment, while the research group used the ambroxol on the basis of the control group, and the clinical curative effect and adverse reactions were evaluated. Results The total effective rate in the research group was higher than that in the control group（93.18% vs 75.00%）,（χ2=5.436,P=0.012）,and the difference in the incidence rate of adverse reactions between the research group and the control group was not statistically significant（11.36% vs 15.91%）, and the difference between the two groups was not statistically significant（χ2=0.386,P=0.072）, after treatment, the PEF,FVC, FEV1/FVC in the research group were higher than those in the control group（t=3.585,3.859,5.856,P=0.023,0.021,0.009）. Conclusion The curative effect of ambroxol in patients with chronic obstructive pulmonary diseases combined with pulmonary tuberculosis is definite, without increasing the adverse reactions of drugs,which is suitable for clinical promotion.